Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. (Q42728611)

5 November 2017

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. (English)

1 reference

5 November 2017

1 reference

Kenneth E Palmer

2

0 references

Dominique Schols

object named as

Dominique Schols

series ordinal

3

0 references

author name string

Geoffrey Férir

series ordinal

1

1 reference

PubMed ID

21802104

5 November 2017

language of work or name

English

0 references

publication date

28 July 2011

1 reference

5 November 2017

1 reference

5 November 2017

417

1 reference

5 November 2017

2

1 reference

5 November 2017

253-258

1 reference

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

5 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

The HIV-1 subtype C epidemic in South America is linked to the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Selection of T1249-resistant human immunodeficiency virus type 1 variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Induction of immunity to human immunodeficiency virus type-1 by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.07.004

10.1016/J.VIROL.2011.07.004

7 January 2021

Identifiers

DOI

1 reference

5 November 2017

1 reference

PubMed ID

21802104